Hippocratic AI announced it has acquired Grove AI and launched a dedicated Life Sciences Division, alongside leadership additions including a new president for the unit and a senior executive advisory council, as the company pushes to expand the use of patient-facing generative AI agents across biopharma and medtech workflows.
The company also disclosed a strategic collaboration with Boston Consulting Group and BCG X to help pharmaceutical and medical technology clients develop and implement generative AI programs spanning R&D, clinical trials, commercialization, and post-market patient engagement.
Hippocratic AI, which positions its agents as non-diagnostic and not permitted to prescribe or diagnose, said the expansion is intended to accelerate adoption in regulated environments by pairing domain-specific models with safety testing and governance frameworks. The company’s agents run on its Polaris safety architecture, which it said is designed to support clinical reasoning and enterprise auditability at scale.
Munjal Shah, Hippocratic AI’s co-founder and chief executive, said the company is “strategically” widening its life sciences footprint through the Grove AI acquisition, the president appointment, the creation of an executive advisory council, and the BCG partnership.
The Grove AI acquisition adds a team focused on agentic AI for pharma R&D and clinical trial operations, Hippocratic AI said, and becomes a central component of the new Life Sciences Division. Grove AI’s platform supported more than 10 million patient interactions over the past year, according to the companies, and was used to identify automation opportunities across clinical research and development workflows.
Hippocratic AI said the deal brings two core offerings into its portfolio: an always-on multilingual agent called “Grace” that supports patient engagement, recruitment, and follow-up across voice, text, and email, and Grove AI PRM, a participant relationship management platform designed to orchestrate AI-driven interactions with transparency, human oversight, and regulatory alignment.
The company said it is currently collaborating with five global pharmaceutical companies to deploy AI agents for patient and provider engagement at enterprise scale.
To shape product direction and industry fit, Hippocratic AI also formed a Life Sciences Executive Advisory Panel that includes Jim Meyers, former chief commercial officer at Gilead Sciences; Michael Norton, former vice president of global medical affairs at AbbVie; David Pierce, former president of MedSurg, Endoscopy, and Urology at Boston Scientific; and Richard Klausner, former director of the National Cancer Institute and a co-founder of multiple biotechnology companies.
Operationally, the new Life Sciences Division will be led by Dr. Ahad Wahid, M.D., who was appointed president of life sciences. Hippocratic AI said Wahid previously served as an NHS surgeon and as a member of the UK General Medical Council’s Quality Assurance Board, and later spent a decade as a partner at Boston Consulting Group advising healthcare organizations on AI and transformation initiatives. Wahid said his focus will be deploying agentic AI “responsibly, measurably, and at enterprise scale” without compromising safety or regulatory integrity.
The BCG collaboration is intended to help clients align generative AI programs with commercial, R&D, and medical affairs priorities, with an emphasis on governance, implementation, and measurable return on investment. Ashkan Afhkami, a BCG managing director and senior partner and global leader for the Health Care practice at BCG X, said the effort is aimed at “closing the value gap” by combining Hippocratic AI’s agent platform with BCG’s strategy and governance experience and BCG X’s healthcare commercial AI capabilities.
Hippocratic AI said the broader push follows its recent $126 million Series C financing, noting that a portion of the proceeds had been earmarked for M&A. The company said it has logged more than 150 million clinical interactions to date and has raised $404 million in total funding from investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVentures, Premji Invest, SV Angel, CapitalG, and multiple health systems.
KEY QUOTES:
“Real impact in the life sciences sector requires deeply specialized models, exhaustive safety testing, and LLM safety architectures built to operate within highly regulated environments. That is why Hippocratic AI has strategically expanded its life sciences leadership – acquiring Grove AI, appointing a dedicated President of Life Sciences, convening a world-class Executive Advisory Council, and partnering with Boston Consulting Group.”
Munjal Shah, Co-founder and CEO, Hippocratic AI
“At Grove AI, we built the leading agentic AI solution for pharma R&D by working directly with clinical teams and patients at scale. By joining Hippocratic AI, we can build on that foundation and accelerate the delivery of these capabilities to a much broader set of life sciences organizations, combining our innovation with Hippocratic AI’s enterprise scale.”
Tran Le, Co-Founder, Grove AI
“With our combined expertise, Hippocratic AI and Grove AI are uniquely positioned to lead the agentic AI transformation at a critical inflection point for the life sciences industry.”
Sohit Gatiganti, Co-Founder, Grove AI
“I decided to join Hippocratic AI as an advisor due to the team’s commitment to innovation that puts the patient and patient safety first. Their proven track record of supporting millions of patient clinical calls, powered by the Polaris Constellation Architecture, uniquely positions them to continue to drive meaningful change across life sciences. I am excited to apply my extensive industry experience during this pivotal period to help deepen the company’s vertical expertise and navigate this complex landscape.”
Jim Meyers, Former Chief Commercial Officer, Gilead Sciences
“Hippocratic AI is building what life sciences has been waiting for: generative AI that can scale globally without compromising safety or regulatory integrity. The acquisition of Grove AI, combined with our expanded leadership team, advisory council, and collaboration with BCG, gives us the foundation to further operationalize agentic AI across research, clinical, and patient engagement workflows. My focus is ensuring these technologies are deployed responsibly, measurably, and at enterprise scale so innovation translates into real outcomes for patients and organizations alike.”
Dr. Ahad Wahid, M.D., President of Life Sciences, Hippocratic AI
“This collaboration is about closing the value gap in the industry by bringing together Hippocratic AI’s sophisticated AI agent platform, BCG’s strategy and governance expertise, and BCG X’s Health Care Commercial AI solution to help clients turn potential into measurable business value.”
Ashkan Afhkami, Managing Director and Senior Partner, and Global Leader for the Health Care practice, BCG X
